Physician profile
Davida F Kruger
NPI 1497897961
$738,657.52
in general payments reported to CMS, 2019-2025
17 companies · $208K in 2025
The $208K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127K · 2022: $147K · 2023: $153K · 2024: $103K · 2025: $208K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Consulting Fee: $102K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $94K · Travel and Lodging: $67K · Food and Beverage: $12K · Honoraria: $7,375 · Education: $19.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $183,129.12 |
| Consulting Fee | $101,651.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $93,792.00 |
| Travel and Lodging | $66,664.43 |
| Food and Beverage | $11,913.60 |
| Honoraria | $7,375.00 |
| Education | $19.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $209,877.04 | 2021-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $178,443.97 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $97,978.22 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $90,638.44 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Insulet Corporation | $61,700.54 | 2023-2025 | Omnipod, Omnipod |
| Cequr Corporation | $23,351.06 | 2022-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $21,875.15 | 2021-2025 | |
| Corcept Therapeutics | $10,635.83 | 2024-2025 | Korlym |
| Embecta Corp. | $9,830.00 | 2023-2024 | |
| Eli Lilly and Company | $9,765.99 | 2021-2025 | |
| Mannkind Corporation | $6,362.24 | 2022-2025 | |
| Medtronic, INC. | $5,741.86 | 2023-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $4,186.82 | 2021-2022 | |
| Sequel Med Tech, LLC | $4,101.44 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $2,633.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $1,409.00 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $126.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davida Kruger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.